Clare Scott

Clare Scott is a medical oncologist whose translational research has characterized the distinct biology of mucinous ovarian carcinoma — an entity with worse outcomes on standard platinum-paclitaxel and fundamentally different from high-grade serous ovarian cancer. Her group has demonstrated high KRAS G12D mutation prevalence and HER2 amplification in mucinous ovarian cancer, providing rationale for KRAS-targeted and HER2-directed therapies. She leads Australian ovarian cancer clinical trials and advocates for histotype-specific clinical trial designs rather than lumping all ovarian cancers together.